Literature DB >> 29894447

Corrected QT Interval Prolongation in Hospitalized Pediatric Patients Receiving Methadone.

Amy J Schwinghammer1, Machelle D Wilson2, Brent A Hall1.   

Abstract

OBJECTIVES: Methadone is often used in pediatric patients to prevent or treat opioid withdrawal after prolonged sedation. Prolonged corrected QT interval is an important adverse effect of methadone because it can progress to torsades de pointes, a potentially fatal dysrhythmia. The prevalence of corrected QT interval prolongation and contributing risk factors are not well defined in hospitalized pediatric patients receiving methadone. The study purpose was to identify the frequency and risk factors of corrected QT interval prolongation in hospitalized pediatric patients receiving methadone.
DESIGN: Retrospective cohort study.
SETTING: Tertiary academic pediatric hospital, University of California Davis Children's Hospital, Sacramento, CA. PATIENTS: Cohort of 89 pediatric patients (birth to 18 yr) who received at least one dose of methadone while hospitalized.
INTERVENTIONS: Retrospective data over 7.5 years were obtained from the electronic health record.
MEASUREMENTS AND MAIN RESULTS: From the cohort, 45 patients (50.6%) had documented corrected QT interval prolongation (≥ 450 ms) during the study period. No episodes of torsades de pointes were identified. In univariate analyses, higher maximum methadone doses were associated with a prolonged corrected QT interval (0.98 vs 0.59 mg/kg/d; odds ratio, 2.56; 1.15-5.70). Corrected QT interval prolongation occurred more frequently in patients with cardiac disease (63% vs 41%; p = 0.10). No factors were statistically significant in the multivariate analysis.
CONCLUSIONS: In hospitalized pediatric patients receiving methadone, corrected QT interval prolongation was common, but no episodes of torsades de pointes were documented. Risk factors that have been identified in adults were not associated with prolongation in our study population.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29894447      PMCID: PMC6086758          DOI: 10.1097/PCC.0000000000001601

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  16 in total

1.  Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy.

Authors:  Andrew K Roy; Catherine McCarthy; Gareth Kiernan; Catherine McGorrian; Eamon Keenan; Niall G Mahon; Brion Sweeney
Journal:  Addiction       Date:  2012-02-28       Impact factor: 6.526

2.  Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society.

Authors:  Roger Chou; Ricardo A Cruciani; David A Fiellin; Peggy Compton; John T Farrar; Mark C Haigney; Charles Inturrisi; John R Knight; Shirley Otis-Green; Steven M Marcus; Davendra Mehta; Marjorie C Meyer; Russell Portenoy; Seddon Savage; Eric Strain; Sharon Walsh; Lonnie Zeltzer
Journal:  J Pain       Date:  2014-04       Impact factor: 5.820

3.  Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.

Authors:  Georg B Ehret; Cathy Voide; Marianne Gex-Fabry; Jocelyne Chabert; Dipen Shah; Barbara Broers; Valérie Piguet; Thierry Musset; Jean-Michel Gaspoz; Arnaud Perrier; Pierre Dayer; Jules A Desmeules
Journal:  Arch Intern Med       Date:  2006-06-26

Review 4.  The use of methadone to facilitate opioid weaning in pediatric critical care patients: a systematic review of the literature and meta-analysis.

Authors:  Leslie A Dervan; Beryl Yaghmai; Robert Scott Watson; Fredric M Wolf
Journal:  Paediatr Anaesth       Date:  2017-01-20       Impact factor: 2.556

5.  QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.

Authors:  Ellen C Pearson; Raymond L Woosley
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-11       Impact factor: 2.890

Review 6.  Methadone-associated Q-T interval prolongation and torsades de pointes.

Authors:  John Stringer; Christopher Welsh; Anthony Tommasello
Journal:  Am J Health Syst Pharm       Date:  2009-05-01       Impact factor: 2.637

Review 7.  Measurement and estimation of GFR in children and adolescents.

Authors:  George J Schwartz; Dana F Work
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-09       Impact factor: 8.237

8.  Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes.

Authors:  Mori J Krantz; Ilana B Kutinsky; Alastair D Robertson; Philip S Mehler
Journal:  Pharmacotherapy       Date:  2003-06       Impact factor: 4.705

9.  Prevalence of long QTc interval in methadone maintenance patients.

Authors:  Francina Fonseca; Julio Marti-Almor; Antoni Pastor; Mercè Cladellas; Magí Farré; Rafael de la Torre; Marta Torrens
Journal:  Drug Alcohol Depend       Date:  2008-09-05       Impact factor: 4.492

Review 10.  Tolerance and withdrawal from prolonged opioid use in critically ill children.

Authors:  Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson
Journal:  Pediatrics       Date:  2010-04-19       Impact factor: 7.124

View more
  3 in total

Review 1.  Methadone: applications in pediatric anesthesiology and critical care medicine.

Authors:  Joseph D Tobias
Journal:  J Anesth       Date:  2021-01-12       Impact factor: 2.078

Review 2.  Emerging Challenges to the Safe and Effective Use of Methadone for Cancer-Related Pain in Paediatric and Adult Patient Populations.

Authors:  Kyle P Edmonds; Ila M Saunders; Andrew Willeford; Toluwalase A Ajayi; Rabia S Atayee
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

3.  Drug-induced prolonged corrected QT interval in patients with methadone and opium overdose.

Authors:  Davood Soroosh; Mahbubeh Neamatshahi; Bahram Zarmehri; Samaneh Nakhaee; Omid Mehrpour
Journal:  Subst Abuse Treat Prev Policy       Date:  2019-02-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.